Endpoints Cancer R&D Summit: The Outlook for Cancer Gene Therapies
Summary: What hurdles need to be overcome before gene therapy is a major new modality in the cancer therapy arsenal? We’ll look at manufacturing, viral vectors, and discuss the most promising approaches coming to the clinic.
Thomas VanCott, Chief Technology and Strategy Officer at Catalent, Jo Brewer, Vice President Allogeneic Research at Adaptimmune, Brian Champion, Chief Scientific Officer at Psioxus, and Endpoints News editor John Carroll discuss cell and gene therapies as cancer treatments including the complexities in manufacturing these advanced biotherapeutics.